In this week’s View, Dr. Eagle discusses the association of blood viscosity with mortality among patients hospitalized with COVID-19, then looks at a systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Finally, Dr. Eagle summarizes an open-label, blinded-outcome, randomized non-inferiority trial that examined thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke.

Clinical Topics: Cardiac Surgery, Cardio-Oncology, COVID-19 Hub, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Vascular Medicine, Cardiac Surgery and Heart Failure, Lipid Metabolism, Novel Agents, Acute Heart Failure, Interventions and Imaging, Interventions and Vascular Medicine, Angiography, Nuclear Imaging, Anticoagulation Management, Prevention

Keywords: Hospital Mortality, COVID-19, Blood Viscosity, Hematocrit, Inflammation Mediators, Blood Coagulation, Cardiomyopathies, Thromboembolism, Stroke Volume, Angiotensin Receptor Antagonists, Cardiotoxicity, Renin-Angiotensin System, Angiotensin-Converting Enzyme Inhibitors, Breast Neoplasms, Ventricular Function, Left, Trastuzumab, Anthracyclines, Ventricular Dysfunction, Left, Heart Failure, Tissue Plasminogen Activator, Ischemic Stroke, Coronary Occlusion, Thrombectomy, Stents, Thrombolytic Therapy, Intracranial Hemorrhages, Angiography, EaglesEyeView

< Back to Listings